May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreous Injection of VEGF-R2antisense Oligonucleotides Limits the Growth of Retinal New Vessels in the Mouse Rop Model
Author Affiliations & Notes
  • F. Valamanesh
    Physiopathology of ocular diseases: therapeutic innovations, CRC UMRS 872, Paris, France
    Rothschild ophthalmic Foundation, Paris, France
  • T. Hagit
    School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel
  • M. Hagedorn
    INSERM E0113, Bordeaux, France
  • Y. de Kozak
    Physiopathology of ocular diseases: therapeutic innovations, CRC UMRS 872, Paris, France
  • S. Benita
    School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel
  • G. Lambert
    Novagali, Evry, France
  • C. Gandolphe
    Physiopathology of ocular diseases: therapeutic innovations, CRC UMRS 872, Paris, France
  • F. Behar-Cohen
    Physiopathology of ocular diseases: therapeutic innovations, CRC UMRS 872, Paris, France
    Rothschild ophthalmic Foundation, Paris, France
  • Footnotes
    Commercial Relationships  F. Valamanesh, None; T. Hagit, None; M. Hagedorn, None; Y. de Kozak, None; S. Benita, None; G. Lambert, None; C. Gandolphe, None; F. Behar-Cohen, None.
  • Footnotes
    Support  CRAFT QLK6-CT-2002-71548
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 528. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Valamanesh, T. Hagit, M. Hagedorn, Y. de Kozak, S. Benita, G. Lambert, C. Gandolphe, F. Behar-Cohen; Intravitreous Injection of VEGF-R2antisense Oligonucleotides Limits the Growth of Retinal New Vessels in the Mouse Rop Model. Invest. Ophthalmol. Vis. Sci. 2008;49(13):528. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the effects of intravitreous delivery of VEGF-R2 (KDR) antisense oligonucleotide in a cationic nanoemulsion on retinal neovascularization in the mouse ROP model.

Methods: : The effect of different sequences of partial phosphorothioate antisense oligonucleotides (ODN) directed at VEGFR-2 were evaluated on VEGF-induced HUVEC proliferation. The down-regulation of VEGFR-2 by specific anti VEGFR-2 antisense oligonucleotide was also evaluated by RT-PCR and western blot analysis. The tolerance of different formulations of cationic nanoemulsions was evaluated on rat retinal pigment epithelial and retinal glial Müller cells in vitro using the MTT test. For in vivo studies, one µl of cationic nanoemulsion containing anti VEGFR-2 ODN (25µM), sense and scrambled ODN sequences and vehicle emulsion were injected in the vitreous of ROP neonatal mice at PN13 and 15. At PN17, retinal vascular endothelial cell proliferation was quantified by direct cell count.

Results: : In vitro, a specific and dose-dependent (0.5 to 5µM) inhibition of VEGF-induced HUVEC proliferation was observed when antisense oligonucleotide directed at VEGFR-2 was added to the cultures. Both RPE and RMG cells tolerated best a 2.5%MCT, DOTAP oil cationic formulation without evident cell toxicity up to10µl/ml. In the ROP model, an inhibition of 23% retinal neovascularization was observed with the free ASODN This inhibition increased to 64% when the AS ODN was vehicled by the MCT/DOTAP cationic nanoemulsion. No inhibition was observed when either the scrambled ODN sequence or the emulsion were used. No histological damages were observed after the intravitreous injections of the cationic nanoemulsion.

Conclusions: : Antisense (ODN) directed at VEGFR-2 (KDR) can be used as specific inhibitor of endothelial cell proliferation. The formulation of specific ODNs in a cationic nanoemulsion may be a safe alternative for ocular gene therapeutic strategies.

Keywords: inhibitory receptors • gene transfer/gene therapy • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×